TAVR in Low Risk Patients: Case Presentations Chad Kliger MD MS - PowerPoint PPT Presentation

Nov 11, 2023 •438 likes •659 views

TAVR in Low Risk Patients: Case Presentations Chad Kliger MD MS Western Regional Director, Structural Heart Disease Assistant Professor of Cardiology, Hofstra School of Medicine Lenox Hill Heart and Lung, Northwell Health Disclosures Within

TAVR in Low Risk Patients: Case Presentations Chad Kliger MD MS Western Regional Director, Structural Heart Disease Assistant Professor of Cardiology, Hofstra School of Medicine Lenox Hill Heart and Lung, Northwell Health
Disclosures Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Consulting Fees/Honoraria Medtronic, Edwards Lifesciences Siemens Healthineers, Philips Healthcare
Low Risk TAVR #1 • 71yo female with HTN, HLD, DM2 on oral meds • Hx of GIB 8yrs ago without recurrent Hgb 10.3 • Asthma, last hospitalization 1yr ago in setting of URI • Presents with progressive dyspnea on exertion – NYHA III • STS 1.86% for isolated SAVR
Low Risk TAVR #1 • Severe AS by TTE, mean gradient 43mmHg, AVA 0.5cm2/m2 • Cath revealed non-obstructive CAD with 30% mid LAD; PA pressure 21mmHg
Low Risk TAVR #1 • Annulus: • Major/min diameter 18.4/24.4mm • Perimeter 67.5mm • Area 345mm2 • SoV >27mm • LVOT: 65mm perimeter • Membranous septum: 3mm
Low Risk TAVR #1 • Rt iliofemoral >6mm • Lt iliofemoral >6mm • Type I aortic arch
Low Risk TAVR #1 – Baseline EKG • NSR with LVH • But … patient focused on potential need for PPM • Proceed with TAVR • 20/23mm S3 vs 26mm CV Evolut Pro
Low Risk TAVR #1 TAVR • 26mm CV Epro • Implantation depth 3mm • No PVL • Hemos: • <2mmHg peak/mean • TTE mean 5mmHg Gueta et al AJC 2011.
Low Risk TAVR #1 – Post-TAVR EKG • Intra-op, immediately post-TAVR • 3hrs post-TAVR, stable to POD#2 • QRS 160ms • QRS 120ms
Low Risk TAVR #1 TAVR and Conduction • New LBBB and Recovery of LVEF • New LBBB and cardiac mortality Nazif et al. EHJ 2014. Riqueiro et al, CCI 2016.
Low Risk TAVR #1 Long-term PPM Complications SURTAVI, Reardon et al NEJM 2017. Palmisano et al, Europace 2013.
Low Risk TAVR #1 • Stable EKG, no events on telemtry • No nodal blockers • Decision made to send patient on real-time event monitor for 30d • No events on monitor • 1yr follow-up, pt doing well Kliger et al US Cardiology Review 2018.
Low Risk TAVR #2 • 70yo male with PMHx of • HTN, HLD • Afib, stopped eliquis 3mo ago for rectus sheath bleed – Hgb 5 • Presents with SOB NYHA III • STS 1.4% for isolated SAVR • TTE revealed severe AS mean gradient 40mmHg, AVA 0.9cm2/AVAi 0.5cm2/m2, nml EF, mild AI • CHADS2-VASc 3 (3.2%) HAS-BLED 3 (5.8%)
Low Risk TAVR #2 • Annulus: • Major/min diameter 23.2/28.5mm • Perimeter 84.9mm • Area 539mm2 • LVOT: Ca +2 , 85.2mm perimeter • SoV >33mm • No thrombus/filling defect in LAA
Low Risk TAVR #2 • Rt iliofemoral >8mm • Lt iliofemoral >6mm • Type II bovine aortic arch
Low Risk TAVR #2 TAVR • Given LVOT Ca +2 , BAV using 20mm TrueFlow balloon • Sentinel Embolic Protection placed • 34mm CV Evolut R • Implantation depth 4mm • Mild PVL • Hemos: • <2mmHg peak/mean • TTE mean 8mmHg
Low Risk TAVR #2 TAVR Reardon et al, NEJM 2019
Low Risk TAVR #2 TAVR Gueta et al AJC 2011.
Low Risk TAVR #2 1mo Post-TAVR • Started on plavix monotherapy for 1mo • Returning in 1wk for LAA closure
Thank You ckliger@northwell.edu

Recommend

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable,

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients Susheel Kodali, MD on behalf of The PARTNER Trial Investigators ACC 2015 | San Diego | March 15,

855 views • 43 slides

Prosthesis-Patient Mismatch in 62,125 TAVR Patients An STS/ACC TVT Registry Report Howard C.

Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients An STS/ACC TVT Registry Report Howard C. Herrmann, MD University of Pennsylvania Philadelphia Howard C. Herrmann MD University of Pennsylvania Samuel

275 views • 16 slides

Disclosures I have nothing to disclose 1 9/21/2015 Why is TAVR Important to You?

9/21/2015 Anesthesia For TAVR Lundy J. Campbell, MD Professor of Clinical Anesthesia Chief, Division of Adult Cardiothoracic Anesthesia Disclosures I have nothing to disclose 1 9/21/2015 Why is TAVR Important to You? Ability to

338 views • 9 slides

PRAVEEN PANGULURI, MD OCTOBER 29, 2019 PRE TAVR ECHO PRE CT MEASUREMENTS Annulus area: 398 mm2

PRAVEEN PANGULURI, MD OCTOBER 29, 2019 PRE TAVR ECHO PRE CT MEASUREMENTS Annulus area: 398 mm2 LVOT area: 366 mm2 Dimensions: 19x27mm Dimensions: 18x27mm PRE CT MEASUREMENTS VALVE DEPLOYMENT IMMEDIATE POST TAVR IMMEDIATE POST TAVR TTE

337 views • 11 slides

Risk communication, transparency What do patients say What do patients understand

Risk communication, transparency What do patients say What do patients understand Ditchley 6, June 1-2, 2016, Cork The slides reflect the speakers personal opinion David H.-U. Haerry, EATG david@haerry.org Carcinogenicity of red

504 views • 11 slides

Risk estimation in high- risk patients . . in everybody!? Nationale Lipidendag 17

Risk estimation in high- risk patients . . in everybody!? Nationale Lipidendag 17 mei 2018 Frank L.J. Visseren Disclosures ZonMw, Wellerdieck-de Goede fonds, Research Leatare foundation, Vrienden UMC Utrecht, Dutch Heart

920 views • 55 slides

JC Virus and The Risk of PML PML is a rare disease of CNS that occurs in patients

Discovery and Development of PML treatments Teresa Compton Vice President, PML and Virology Research Biogen Idec JC Virus and The Risk of PML PML is a rare disease of CNS that occurs in patients immunosuppressed and in patients taking

316 views • 8 slides

Recognising risk factors in patients risk assessment and day surgery Gill Lowe University

Recognising risk factors in patients risk assessment and day surgery Gill Lowe University Hospitals Birmingham 5 th May 2016 Declarations Honoraria (advisory committee) and educational grant to attend meeting: Bayer PLC VTE facts and

228 views • 18 slides

1 MRFIT: CV risk associated with diabetes What is the CVD risk associated Non-diabetic

Outline M ANAGEMENT OF C ARDIOVASCULAR R ISK IN D IABETES Review the cardiovascular risk associated with diabetes Discuss current medical therapies and optimal approach to Have we turned the corner? reducing CVD risk in patients with

610 views • 10 slides

Involvement of patients in PRAC benefit-risk June M Raine Chair, Pharmacovigilance Risk

Involvement of patients in PRAC benefit-risk June M Raine Chair, Pharmacovigilance Risk Assessment Committee An agency of the European Union Outline of presentation What was experience of patient observers in Pharmacovigilance Working Party?

548 views • 16 slides

for Critical Care Dr Jane Eddleston Background: In the UK 170,000 patients undergo

Knowing the Risk: implications for Critical Care Dr Jane Eddleston Background: In the UK 170,000 patients undergo higher-risk non- cardiac surgery each year. Of these patients, 100,000 will develop significant complications.

444 views • 25 slides

Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD

Three-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators TCT 2012 | Miami, FL | October

1.09k views • 60 slides

Precision medicine with prediction tools in high CV risk patients Symposium New concepts and

Precision medicine with prediction tools in high CV risk patients Symposium New concepts and models in CV risk management ESC, Munich August 28, 2018 Frank L.J. Visseren Faculty Disclosure Declaration of financial interests For the

482 views • 27 slides

Risk-Based Coding and Reimbursement What is Risk-Based Coding? Risk-Based Coding Overview A

Risk-Based Coding and Reimbursement What is Risk-Based Coding? Risk-Based Coding Overview A diagnosis coding methodology utilized in risk adjustment models to adjust cost for all patients within a health plan or group Risk

385 views • 23 slides

in Rare Patients " Some day risk will be zero My, oh my Some day pills will be magic And

6/22/2013 Ninewells Hospital & Medical School Some day drugs will be perfect If we try Some day drugs will be perfect " Assessing Therapies And no one will ever die in Rare Patients " Some day risk will be zero My, oh my Some

355 views • 23 slides

Pr Prevention Of f primary ry Fo Foot Ulc lcers in hig igh-risk Dia iabetes patients (PrO

Pr Prevention Of f primary ry Fo Foot Ulc lcers in hig igh-risk Dia iabetes patients (PrO rOFoUnD): A clu luster randomised tr trial of f 3D pri rinted In Insoles Versus Standard Care North West Coast Clinical Network Dr Paul

403 views • 22 slides

after TAVR Key Messages from NeuroARC Alexandra Lansky, MD Professor of Medicine, Section of

The Compelling Saga of Strokes after TAVR Key Messages from NeuroARC Alexandra Lansky, MD Professor of Medicine, Section of Cardiology Yale School of Medicine Disclosure Statement of Financial Interest Within the past 12 months, I or my

577 views • 18 slides

Mole Mapping: Managing High Risk Patients through Imaging 1 Disclosures Chief

Mole Mapping: Managing High Risk Patients through Imaging 1 Disclosures Chief Medical Officer for MoleSafe USA, LLC 2 Mole Mapping: Managing High Risk Patients through Imaging This session will focus on utilizing imaging

398 views • 12 slides

Surgical Aortic Valve Replacement in Intermediate Risk Patients Results From The PARTNER 2A and

Cost-Effectiveness of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate Risk Patients Results From The PARTNER 2A and Sapien-3 Intermediate Risk Trials David J. Cohen, M.D., M.Sc. On behalf of the PARTNER 2 Investigators

617 views • 26 slides

Will New TAVR Systems or Accessory Devices Make a Difference? Samir Kapadia, MD Professor of

Strokes and Paravalvular Regurgitation Will New TAVR Systems or Accessory Devices Make a Difference? Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic All faculty disclosures are

329 views • 28 slides

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial Interest Within the past 12 months, I

523 views • 30 slides

Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management

Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management Considerations (present and future) Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Conflict

710 views • 42 slides

inflammatory state in high CV-risk patients: Lp Lp(a) Nederlandse Lipiden Academie: 4e

Targeting cell metabolism to decrease the pro- inflammatory state in high CV-risk patients: Lp Lp(a) Nederlandse Lipiden Academie: 4e Nationale Lipidendag 17 mei 2018, Paushuize, Utrecht Jeffrey Kroon, PhD Vascular Medicine, AMC, Amsterdam

383 views • 21 slides

Ticagrelor With AspIrin or ALone In HiGH-Risk Patients After Coronary InTervention Roxana

Ticagrelor With AspIrin or ALone In HiGH-Risk Patients After Coronary InTervention Roxana Mehran, MD @Drroxmehran on behalf of the TWILIGHT Investigators Icahn School of Medicine at Mount Sinai, New York, NY ClinicalTrials.gov Number:

302 views • 16 slides